collection
https://read.qxmd.com/read/31895595/antidepressant-prescriptions-including-tricyclics-continue-to-increase-in-canadian-children
#1
JOURNAL ARTICLE
Aysha Lukmanji, Tamara Pringsheim, Andrew G Bulloch, David G Stewart, Parco Chan, Ali Tehrani, Scott B Patten
Objective: Few studies have longitudinally followed trends in antidepressant prescribing for Canadian children following the Black Box warning issued in 2004. Using a national data source, we aim to describe trends in antidepressant recommendations for Canadian children ages 1-18 during 2012 to 2016. Methods: A database called the Canadian Disease and Therapeutic Index (CDTI), provided by IQVIA, was used to conduct analyses. The CDTI dataset collects a quarterly sample of pediatric antidepressant recommendations, projected using a weight procedure from a dynamic sample of 652 Canadian office-based physicians...
December 31, 2019: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/29095133/stepped-care-in-primary-care-guided-self-help-and-face-to-face-cognitive-behavioural-therapy-for-common-mental-disorders-a-randomized-controlled-trial
#2
RANDOMIZED CONTROLLED TRIAL
Sigrid Salomonsson, Fredrik Santoft, Elin Lindsäter, Kersti Ejeby, Brjánn Ljótsson, Lars-Göran Öst, Martin Ingvar, Mats Lekander, Erik Hedman-Lagerlöf
BACKGROUND: Common mental disorders (CMD) cause large suffering and high societal costs. Cognitive behavioural therapy (CBT) can effectively treat CMD, but access to treatment is insufficient. Guided self-help (GSH) CBT, has shown effects comparable with face-to-face CBT. However, not all patients respond to GSH, and stepping up non-responders to face-to-face CBT, could yield larger response rates. The aim was to test a stepped care model for CMD in primary care by first evaluating the effects of GSH-CBT and secondly, for non-responders, evaluating the additional effect of face-to-face CBT...
July 2018: Psychological Medicine
https://read.qxmd.com/read/28858450/ketamine-for-depression-5-potential-pharmacokinetic-and-pharmacodynamic-drug-interactions
#3
REVIEW
Chittaranjan Andrade
Ketamine, administered in subanesthetic doses, is gaining recognition as an off-label treatment for severe and even treatment-refractory depression. This article explores potential pharmacokinetic and pharmacodynamic drug interactions of relevance to the use of ketamine in depression. Sparse evidence suggests that ketamine will not induce clinically significant drug interactions except to the extent that these are predictable by its clinical actions. A small body of literature indicates that drugs that induce cytochrome P450 (CYP)2B6 and CYP3A4 will reduce exposure to ketamine and that drugs that inhibit these enzymes will increase exposure to ketamine...
July 2017: Journal of Clinical Psychiatry
https://read.qxmd.com/read/28838328/backing-into-the-future-pharmacological-approaches-to-the-management-of-resistant-depression
#4
REVIEW
P J Cowen
Pragmatic studies indicate that a substantial number of depressed patients do not remit with current first-line antidepressant treatments and after two failed treatment steps the chance of remission with subsequent therapies is around 15%. This paper focuses on current evidence for pharmacological treatments in resistant depression as well as possible future developments. For patients who have failed to respond to two antidepressant trials, augmentation with atypical antipsychotic drugs, specifically quetiapine and aripiprazole, has the best evidence for efficacy, though older treatments such as lithium and triiodothyronine still have utility...
November 2017: Psychological Medicine
https://read.qxmd.com/read/28731778/a-pharmacologic-algorithm-for-youth-who-are-at-high-risk-for-bipolar-disorder
#5
RANDOMIZED CONTROLLED TRIAL
Christopher D Schneck, Kiki D Chang, Manpreet K Singh, Melissa P DelBello, David J Miklowitz
OBJECTIVE: Depression and brief periods of manic symptoms are linked to a significant risk of progression to bipolar disorder (BD) in children who have a first-degree relative with BD I or II. However, little evidence exists to guide the pharmacologic management of children with these high-risk phenotypes. We propose a pharmacological treatment algorithm for high-risk youth and present results on its use in a study of children with a first-degree relative with BD. METHODS: Subjects were 40 youth (mean 12...
November 2017: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/28684405/sleep-loss-as-a-trigger-of-mood-episodes-in-bipolar-disorder-individual-differences-based-on-diagnostic-subtype-and-gender
#6
JOURNAL ARTICLE
Katie Swaden Lewis, Katherine Gordon-Smith, Liz Forty, Arianna Di Florio, Nick Craddock, Lisa Jones, Ian Jones
Background Sleep loss may trigger mood episodes in people with bipolar disorder but individual differences could influence vulnerability to this trigger. Aims To determine whether bipolar subtype (bipolar disorder type I (BP-I) or II (BD-II)) and gender were associated with vulnerability to the sleep loss trigger. Method During a semi-structured interview, 3140 individuals (68% women) with bipolar disorder (66% BD-I) reported whether sleep loss had triggered episodes of high or low mood. DSM-IV diagnosis of bipolar subtype was derived from case notes and interview data...
September 2017: British Journal of Psychiatry
https://read.qxmd.com/read/27604566/ketamine-treatment-and-global-brain-connectivity-in-major-depression
#7
JOURNAL ARTICLE
Chadi G Abdallah, Lynnette A Averill, Katherine A Collins, Paul Geha, Jaclyn Schwartz, Christopher Averill, Kaitlin E DeWilde, Edmund Wong, Alan Anticevic, Cheuk Y Tang, Dan V Iosifescu, Dennis S Charney, James W Murrough
Capitalizing on recent advances in resting-state functional connectivity magnetic resonance imaging (rs-fcMRI) and the distinctive paradigm of rapid mood normalization following ketamine treatment, the current study investigated intrinsic brain networks in major depressive disorder (MDD) during a depressive episode and following treatment with ketamine. Medication-free patients with MDD and healthy control subjects (HC) completed baseline rs-fcMRI. MDD patients received a single infusion of ketamine and underwent repeated rs-fcMRI at 24 h posttreatment...
May 2017: Neuropsychopharmacology
https://read.qxmd.com/read/28658489/association-of-electroconvulsive-therapy-with-psychiatric-readmissions-in-us-hospitals
#8
JOURNAL ARTICLE
Eric P Slade, Danielle R Jahn, William T Regenold, Brady G Case
Importance: Although electroconvulsive therapy (ECT) is considered the most efficacious treatment available for individuals with severe affective disorders, ECT's availability is limited and declining, suggesting that information about the population-level effects of ECT is needed. Objective: To examine whether inpatient treatment with ECT is associated with a reduction in 30-day psychiatric readmission risk in a large, multistate sample of inpatients with severe affective disorders...
August 1, 2017: JAMA Psychiatry
https://read.qxmd.com/read/28448702/ketamine-for-depression-1-clinical-summary-of-issues-related-to-efficacy-adverse-effects-and-mechanism-of-action
#9
REVIEW
Chittaranjan Andrade
Ketamine is an anesthetic drug that is also used for off-label indications such as the mediation of analgesia and sedation in various settings. It is additionally recognized as an agent with antidepressant potential. For depression, it is most commonly administered as a slow intravenous infusion in subanesthetic doses (usually 0.5 mg/kg). As an antidepressant, is strikingly different from conventional antidepressant drugs in that it brings about rapid and marked attenuation of depressive symptoms even in patients with refractory depression...
April 2017: Journal of Clinical Psychiatry
https://read.qxmd.com/read/26628905/the-neurocognitive-functioning-in-bipolar-disorder-a-systematic-review-of-data
#10
JOURNAL ARTICLE
Eirini Tsitsipa, Konstantinos N Fountoulakis
BACKGROUND: During the last decades, there have been many different opinions concerning the neurocognitive function in Bipolar disorder (BD). The aim of the current study was to perform a systematic review of the literature and to synthesize the data in a comprehensive picture of the neurocognitive dysfunction in BD. METHODS: Papers were located with searches in PubMed/MEDLINE, through June 1st 2015. The review followed a modified version of the recommendations of the Preferred Items for Reporting of Systematic Reviews and Meta-Analyses statement...
2015: Annals of General Psychiatry
https://read.qxmd.com/read/26421634/association-between-placebo-activated-neural-systems-and-antidepressant-responses-neurochemistry-of-placebo-effects-in-major-depression
#11
RANDOMIZED CONTROLLED TRIAL
Marta Peciña, Amy S B Bohnert, Magdalena Sikora, Erich T Avery, Scott A Langenecker, Brian J Mickey, Jon-Kar Zubieta
IMPORTANCE: High placebo responses have been observed across a wide range of pathologies, severely impacting drug development. OBJECTIVE: To examine neurochemical mechanisms underlying the formation of placebo effects in patients with major depressive disorder (MDD). DESIGN, SETTING, AND PARTICIPANTS: In this study involving 2 placebo lead-in phases followed by an open antidepressant administration, we performed a single-blinded 2-week crossover randomized clinical trial of 2 identical oral placebos (described as having either active or inactive fast-acting antidepressant-like effects) followed by a 10-week open-label treatment with a selective serotonin reuptake inhibitor or, in some cases, another agent as clinically indicated...
November 2015: JAMA Psychiatry
https://read.qxmd.com/read/26183461/the-suicide-prevention-effect-of-lithium-more-than-20%C3%A2-years-of-evidence-a-narrative-review
#12
JOURNAL ARTICLE
U Lewitzka, E Severus, R Bauer, P Ritter, B Müller-Oerlinghausen, M Bauer
The management and treatment of patients with suicidal behavior is one of the most challenging tasks for health-care professionals. Patients with affective disorders are at high risk for suicidal behavior, therefore, should be a target for prevention. Numerous international studies of lithium use have documented anti-suicidal effects since the 1970s. Despite the unambiguous evidence of lithium's anti-suicidal effects and recommendations in national and international guidelines for its use in acute and maintenance therapy of affective disorders, the use of lithium is still underrepresented...
December 2015: International Journal of Bipolar Disorders
https://read.qxmd.com/read/26184990/psychiatrists-fear-of-death-is-associated-with-negative-emotions-toward-borderline-personality-disorder-patients
#13
JOURNAL ARTICLE
Ehud Bodner, Amit Shrira, Hagai Hermesh, Menachem Ben-Ezra, Iulian Iancu
This study examines the relationship between psychiatrists׳ fear of death and negative emotions toward patients with borderline personality disorder (BPD). A survey (N=120) demonstrated that fear of death is associated with stronger negative attitudes toward BPD patients, after controlling for attitudes toward suicide. Our findings emphasize the importance of psychiatrists׳ awareness to their fear of death as a relevant factor for their emotions toward BPD patients.
August 30, 2015: Psychiatry Research
https://read.qxmd.com/read/26035204/effects-of-n-acetyl-cysteine-on-suicidal-ideation-in-bipolar-depression
#14
LETTER
Astrid Waterdrinker, Michael Berk, Kamalesh Venugopal, Marta Rapado-Castro, Alyna Turner, Olivia M Dean
No abstract text is available yet for this article.
May 2015: Journal of Clinical Psychiatry
https://read.qxmd.com/read/26085041/ziprasidone-augmentation-of-escitalopram-for-major-depressive-disorder-efficacy-results-from-a-randomized-double-blind-placebo-controlled-study
#15
RANDOMIZED CONTROLLED TRIAL
George I Papakostas, Maurizio Fava, Lee Baer, Michaela B Swee, Adrienne Jaeger, William V Bobo, Richard C Shelton
OBJECTIVE: The authors sought to test the efficacy of adjunctive ziprasidone in adults with nonpsychotic unipolar major depression experiencing persistent symptoms after 8 weeks of open-label treatment with escitalopram. METHOD: This was an 8-week, randomized, double-blind, parallel-group, placebo-controlled trial conducted at three academic medical centers. Participants were 139 outpatients with persistent symptoms of major depression after an 8-week open-label trial of escitalopram (phase 1), randomly assigned in a 1:1 ratio to receive adjunctive ziprasidone (escitalopram plus ziprasidone, N=71) or adjunctive placebo (escitalopram plus placebo, N=68), with 8 weekly follow-up assessments...
December 2015: American Journal of Psychiatry
https://read.qxmd.com/read/26045352/maternal-depression-during-pregnancy-and-offspring-depression-in-adulthood-role-of-child-maltreatment
#16
JOURNAL ARTICLE
Dominic T Plant, Carmine M Pariante, Deborah Sharp, Susan Pawlby
BACKGROUND: Studies have shown that maternal depression during pregnancy predicts offspring depression in adolescence. Child maltreatment is also a risk factor for depression. AIMS: To investigate (a) whether there is an association between offspring exposure to maternal depression in pregnancy and depression in early adulthood, and (b) whether offspring child maltreatment mediates this association. METHOD: Prospectively collected data on maternal clinical depression in pregnancy, offspring child maltreatment and offspring adulthood (18-25 years) DSM-IV depression were analysed in 103 mother-offspring dyads of the South London Child Development Study...
September 2015: British Journal of Psychiatry
https://read.qxmd.com/read/25838109/autistic-like-traits-in-adult-patients-with-mood-disorders-and-schizophrenia
#17
JOURNAL ARTICLE
Junko Matsuo, Yoko Kamio, Hidetoshi Takahashi, Miho Ota, Toshiya Teraishi, Hiroaki Hori, Anna Nagashima, Reiko Takei, Teruhiko Higuchi, Nobutaka Motohashi, Hiroshi Kunugi
Autism spectrum disorder often co-occurs with other psychiatric disorders. Although a high prevalence of autistic-like traits/symptoms has been identified in the pediatric psychiatric population of normal intelligence, there are no reports from adult psychiatric population. This study examined whether there is a greater prevalence of autistic-like traits/symptoms in patients with adult-onset psychiatric disorders such as major depressive disorder (MDD), bipolar disorder, or schizophrenia, and whether such an association is independent of symptom severity...
2015: PloS One
https://read.qxmd.com/read/25010702/dialectical-behavior-therapy-for-adolescents-with-bipolar-disorder-results-from-a-pilot-randomized-trial
#18
RANDOMIZED CONTROLLED TRIAL
Tina R Goldstein, Rachael K Fersch-Podrat, Maribel Rivera, David A Axelson, John Merranko, Haifeng Yu, David A Brent, Boris Birmaher
OBJECTIVE: The purpose of this study was to conduct a pilot randomized trial of dialectical behavior therapy (DBT) versus psychosocial treatment as usual (TAU) for adolescents diagnosed with bipolar disorder (BP). METHODS: We recruited participants 12-18 years of age with a primary BP diagnosis (I, II, or operationalized not otherwise specified [NOS] criteria) from a pediatric specialty clinic. Eligible patients were assigned using a 2:1 randomization structure to either DBT (n=14) or psychosocial TAU (n=6)...
March 2015: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/25845021/recovery-and-recurrence-following-a-first-episode-of-mania-a-systematic-review-and-meta-analysis-of-prospectively-characterized-cohorts
#19
REVIEW
Andréanne Gignac, Alexander McGirr, Raymond W Lam, Lakshmi N Yatham
OBJECTIVE: Information about recurrence rates is useful in informing clinical practice, but most data with regard to recurrence rates in bipolar patients come from cohorts at different stages of illness. These data are of limited utility in estimating risk of relapse in first-episode bipolar disorder. Therefore, the objective of this investigation was to synthesize available recurrence data after a first episode of mania. DATA SOURCES: We searched MEDLINE, EMBASE, PsycINFO, and Cochrane Central Register of Controlled Trials (CENTRAL) from 1980 to January 24th, 2014, for articles in English, French, or Spanish using (1) bipolar disorder (MeSH term) OR manic/mania, AND (2) first* (episode*, hospitalization* OR admission*) OR time factor (MeSH term), AND (3) recovery, remission, recurrence OR relapse...
September 2015: Journal of Clinical Psychiatry
https://read.qxmd.com/read/25844756/lurasidone-in-the-treatment-of-bipolar-depression-with-mixed-subsyndromal-hypomanic-features-post-hoc-analysis-of-a-randomized-placebo-controlled-trial
#20
RANDOMIZED CONTROLLED TRIAL
Roger S McIntyre, Josephine Cucchiaro, Andrei Pikalov, Hans Kroger, Antony Loebel
OBJECTIVE: Mixed (subsyndromal hypomanic) features are prevalent in patients with bipolar depression and are associated with more severe and complex illness, including increased risk for suicide attempts, higher switch to mania during antidepressant therapy, and a higher rate of recurrence. The aim of this post hoc analysis was to evaluate the efficacy and safety of lurasidone in the treatment of patients with bipolar depression presenting with mixed features. METHOD: Patients with a DSM-IV-TR diagnosis of major depressive episode associated with bipolar I disorder, with or without rapid cycling, and with a Montgomery-Asberg Depression Rating Scale (MADRS) score ≥ 20 and a Young Mania Rating Scale (YMRS) score ≤ 12 were randomly assigned to 6 weeks of double-blind, once-daily treatment with lurasidone 20-60 mg, lurasidone 80-120 mg, or placebo...
April 2015: Journal of Clinical Psychiatry
label_collection
label_collection
4457
1
2
2015-04-10 16:19:37
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.